Meningococcal carriage, meningococcal disease and vaccination

doi:10.1016/S0163-4453(88)96117-8

Journal of Infection

Volume 16, Issue 1, January 1988, Pages 55-58, IN1, 59

https://doi.org/10.1016/S0163-4453(88)96117-8 Get rights and content

Summary

Group A meningococcal carriage rates were determined 6 months before and 6 and 18 months after a mass vaccination campaign with a combined group A and group C meningococcal polysaccharide vaccine in a rural area of The Gambia. During the first pre-vaccination survey, performed during an outbreak of meningococcal disease, the carriage rate was high (16 %). The carriage rate remained high during a second survey made 6 months after a vaccination campaign that covered approximately 90 % of the study population. A year later very few group A meningococcal carriers were found. Membrane protein patterns of isolates obtained before and after vaccination were similar. We conclude that vaccination had little influence on the carriage rate of group A meningococci but that this was influenced by changes in herd immunity or by other unidentified factors.

References (6)

GotschlichEC et al.
Human immunity to the meningococcus. V. The effect of immunization with group C meningococcal polysaccharide on the carrier state
J. Exp Med
(1969)
WahdanMH et al.
A second controlled field trial of a serogroup A meningococcal polysaccharide vaccine in Alexandria
Bull WHO
(1977)
GreenwoodBM et al.
Prevention of secondary cases of meningococcal disease in household contacts by vaccination
Br Med J
(1978)

There are more references available in the full text version of this article.

Cited by (108)

Bacterial capsules
2023, Molecular Medical Microbiology, Third Edition
Capsules are the outmost structures of bacterial and fungal cells. Capsules protect microbial cells from immune recognition and phagocytosis during infection of mammalian hosts. With the exception of the poly-γ-glutamate (PGA) capsule of Bacillus anthracis, other known capsules are all composed of polysaccharides. Certain bacterial species (e.g., B. anthracis and Streptococcus pyogenes) produce only one capsule structure, whereas many others express capsule variants with great biochemical, structural and immunogenic diversity within the same species. The genes for capsule synthesis are typically clustered in a single locus of the bacterial chromosome. The number of genes associated with capsule synthesis range from one in serotype 37 S. pneumoniae to as many as 22 in serotype 16A S. pneumoniae. Different bacterial species can share similar genes or mechanisms for capsule synthesis, reflecting horizontal gene transfer and recombination events. The expression of the capsule genes is often regulated by multiple mechanisms under changing environmental conditions. Finally, the immunogenic properties of capsular polysaccharides have been employed to develop vaccines against several encapsulated pathogens. The capsule biosynthesis pathway is also considered as a promising target for novel antimicrobials.
Meningococcal disease in the Middle East and Africa: Findings and updates from the Global Meningococcal Initiative
2017, Journal of Infection
The Global Meningococcal Initiative (GMI) has recently considered current issues in Middle Eastern and African countries, and produced two recommendations: (i) that vaccination of attendees should be considered for some types of mass-gathering events, as some countries mandate for the Hajj, and (ii) vaccination of people with human immunodeficiency virus should be used routinely, because of increased meningococcal disease (MD) risk. Differences exist between Middle Eastern and African countries regarding case and syndrome definitions, surveillance, and epidemiologic data gaps. Sentinel surveillance provides an overview of trends and prevalence of different capsular groups supporting vaccine selection and planning, whereas cost-effectiveness decisions require comprehensive disease burden data, ideally counting every case. Surveillance data showed importance of serogroup B MD in North Africa and serogroup W expansion in Turkey and South Africa. Success of MenAfriVac^® in the African “meningitis belt” was reviewed; the GMI believes similar benefits may follow development of a low-cost meningococcal pentavalent vaccine, currently in phase 1 clinical trial, by 2022. The importance of carriage and herd protection for controlling invasive MD and the importance of advocacy and awareness campaigns were also highlighted.
Towards understanding the epidemiology of Neisseria meningitidis in the African meningitis belt: a multi-disciplinary overview
2017, International Journal of Infectious Diseases
Neisseria meningitidis is the major cause of seasonal meningitis epidemics in the African meningitis belt. In the changing context of a reduction in incidence of serogroup A and an increase in incidence of serogroups W and C and of Streptococcus pneumoniae, a better understanding of the determinants driving the disease transmission dynamics remains crucial to improving bacterial meningitis control.
The literature was searched to provide a multi-disciplinary overview of the determinants of meningitis transmission dynamics in the African meningitis belt.
Seasonal hyperendemicity is likely predominantly caused by increased invasion rates, sporadic localized epidemics by increased transmission rates, and larger pluri-annual epidemic waves by changing population immunity. Carriage likely involves competition for colonization and cross-immunity. The duration of immunity likely depends on the acquisition type. Major risk factors include dust and low humidity, and presumably human contact rates and co-infections; social studies highlighted environmental and dietary factors, with supernatural explanations.
Efforts should focus on implementing multi-country, longitudinal seroprevalence and epidemiological studies, validating immune markers of protection, and improving surveillance, including more systematic molecular characterizations of the bacteria. Integrating climate and social factors into disease control strategies represents a high priority for optimizing the public health response and anticipating the geographic evolution of the African meningitis belt.
Bacterial Capsules
2014, Molecular Medical Microbiology
Capsules are the outmost structures of bacterial and fungal cells. The capsules protect microbial cells from immune recognition and killing during infection of mammalian hosts. Except for the poly-γ-glutamate (PGA) capsule of Bacillus anthracis, other known capsules are all composed of polysaccharides. Certain bacteria (e.g. B. anthracis and Streptococcus pyogenes) produce only one capsule structure, whereas many other bacteria express capsules with great biochemical, structural and immunological diversity within the same species. This diversity is driven by immune selection from the mammalian hosts. The genes for capsule synthesis are typically clustered in a single locus of bacterial chromosome. The number of genes associated with capsule synthesis ranges from one in serotype 37 Streptococcus pneumoniae to >20 in serotype 38 S. pneumoniae. Different bacterial species can share similar genes or mechanisms for capsule synthesis. The expression of the capsule genes is often regulated by environmental conditions. The capsular polysaccharides are the antigens of the current polysaccharide-based vaccines for S. pneumoniae, Neisseria meningitidis, Haemophilus influenzae and Salmonella enterica serovar Typhi. Certain capsule polymers also have important industrial applications.
Meningococcal vaccines
2012, Vaccines: Sixth Edition
Safety and immunogenicity of an investigational quadrivalent meningococcal CRM<inf>197</inf> conjugate vaccine, MenACWY-CRM, compared with licensed vaccines in adults in Latin America
2010, International Journal of Infectious Diseases
This study compared the investigational quadrivalent meningococcal CRM₁₉₇ conjugate vaccine, MenACWY-CRM, with licensed quadrivalent polysaccharide (MPSV4) and conjugate (MenACWY-D) meningococcal vaccines.
In this phase III multicenter study, 2505 adults (aged 19–55 years) were randomized to receive either MenACWY-CRM or MenACWY-D, and 326 adults (aged 56–65 years) were randomized to receive either MenACWY-CRM or MPSV4. Sera obtained pre-vaccination and at 1-month post-vaccination were tested for serogroup-specific serum bactericidal activity using human complement (hSBA) for immunogenicity non-inferiority and superiority analyses.
The vaccines in all groups were well tolerated. In the 19–55 years age group, post-vaccination geometric mean titers (GMTs) were consistently higher for MenACWY-CRM than for MenACWY-D for all four serogroups. MenACWY-CRM was non-inferior to MenACWY-D for all serogroups, and superior for serogroup Y. In the 56–65 years age group, post-vaccination GMTs were 1.2- to 5.4-fold higher for MenACWY-CRM than for MPSV4 for the four serogroups.
MenACWY-CRM is well tolerated and immunogenic in adults aged 19–65 years, with at least non-inferior immunogenicity compared with the currently licensed meningococcal vaccines.

View all citing articles on Scopus

View full text

Original articleMeningococcal carriage, meningococcal disease and vaccination

Summary

Human immunity to the meningococcus. V. The effect of immunization with group C meningococcal polysaccharide on the carrier state

J. Exp Med

A second controlled field trial of a serogroup A meningococcal polysaccharide vaccine in Alexandria

Bull WHO

Prevention of secondary cases of meningococcal disease in household contacts by vaccination

Br Med J

Original article
Meningococcal carriage, meningococcal disease and vaccination